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Amplicon deep sequencing 
improves Plasmodium falciparum 
genotyping in clinical trials of 
antimalarial drugs
Maria Gruenberg1,2,4, Anita Lerch  1,3,4, Hans-Peter Beck  1,2 & ingrid felger  1,2*
clinical trials monitoring malaria drug resistance require genotyping of recurrent Plasmodium 
falciparum parasites to distinguish between treatment failure and new infection occurring during the 
trial follow up period. Because trial participants usually harbour multi-clonal P. falciparum infections, 
deep amplicon sequencing (AmpSeq) was employed to improve sensitivity and reliability of minority 
clone detection. Paired samples from 32 drug trial participants were Illumina deep-sequenced for five 
molecular markers. Reads were analysed by custom-made software HaplotypR and trial outcomes 
compared to results from the previous standard genotyping method based on length-polymorphic 
markers. Diversity of AmpSeq markers in pre-treatment samples was comparable or higher than length-
polymorphic markers. AmpSeq was highly reproducible with consistent quantification of co-infecting 
parasite clones within a host. Outcomes of the three best-performing markers, cpmp, cpp and ama1-D3, 
agreed in 26/32 (81%) of patients. Discordance between the three markers performed per sample was 
much lower by AmpSeq (six patients) compared to length-polymorphic markers (eleven patients). Using 
AmpSeq for discrimination of recrudescence and new infection in antimalarial drug trials provides highly 
reproducible and robust characterization of clone dynamics during trial follow-up. AmpSeq overcomes 
limitations inherent to length-polymorphic markers. Regulatory clinical trials of antimalarial drugs will 
greatly benefit from this unbiased typing method.
The efficacy of new drugs against Plasmodium falciparum is tested in vivo in clinical trials conducted in malaria 
endemic field sites, where transmission is ongoing. Therefore, trial participants may be exposed to infection by 
new parasite clones during the trial period. New infections (NI) coming in during follow-up can severely com-
promise trial outcomes because detection of recurrent parasitemia in participants is scored as drug failure, despite 
initial successful parasite clearance by the drug under trial. Drug trials conducted in moderate and high transmis-
sion settings thus suffer from underestimation of therapeutic efficacies. Differentiation of true treatment failures 
from new infections is therefore crucial for efficacy trials as well as for drug resistance surveillance in the field.
The problem deriving from parasite clones acquired during the follow-up period was resolved by genotyping 
parasites at the day of treatment and at the day of recurrent parasitemia. Highly diverse length-polymorphic 
antigen markers or microsatellites had been used for this purpose and laboratory and analytical procedures have 
been harmonized at a stakeholder meeting organized by WHO and MMV in 20071. In the past years, we and 
others observed that the established length-polymorphic markers, i.e. genes for merozoite surface protein 1 and 2 
(msp1, msp2) and glutamate-rich protein (glurp), likely are suboptimal, as major size differences between ampli-
cons cause a bias in amplification efficiency, which in multi-clonal infections leads to preferred amplification of 
shorter fragments and loss of long alleles2–10. Therefore, the development of alternative, simple, high-throughput, 
and highly sensitive genotyping techniques is particularly important for discrimination of recrudescent from new 
infections in regulatory trials.
We hypothesized that marker genes rich in single nucleotide polymorphism (SNP) may be superior to 
the standard length-polymorphic markers that contain intragenic tandem repeats. SNP-rich marker genes 
are genotyped by deep sequencing of PCR amplicons (AmpSeq)11–15. Amplification bias, as observed with 
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length-polymorphic markers, should be overcome by choosing amplicons of the same length. The question on 
how the established msp1/msp2/glurp genotyping method compares with AmpSeq regarding marker diversity, 
multiplicity of infection (MOI), and trial outcomes, was addressed by applying both typing techniques to the 
same set of samples.
This study investigated the utility and benefits of amplicon deep sequencing applied for genotyping of P. falci-
parum in a clinical trial of antimalarial drug efficacy. Development, validation and down-selection of molecular 
markers, together with an improved protocol and data analyses pipeline, aimed at a robust and reproducible new 
genotyping technique for PCR-correction of treatment failure rates that is acceptable by regulatory authorities.
Results
Using data from the MalariaGen genome data repository16 we identified highly diverse molecular markers that 
show extensive single nucleotide polymorphism (SNP) according to bioinformatics strategies described earlier15. 
Here, two new P. falciparum AmpSeq markers, cpp and msp7, were developed and validated, which were used 
together with 3 previously identified AmpSeq markers14,15,17 ama1-D3, cpmp, and csp, for differentiation of NI and 
R by deep amplicon sequencing in paired samples from a clinical trial of an antimalarial drug.
Analysis of illumina sequence reads. Starting from DBS, we amplified and sequenced 34 paired pre- and 
post-treatment field samples and 6 control mixtures of P. falciparum in vitro strains HB3 and 3D7 for the five 
markers ama1-D3, cpp, cpmp, csp and msp7 using an Illumina MiSeq platform in paired end mode. Sequence 
reads were processed with software HaplotypR resulting in a median coverage of 13698 [range 2826–21853, 2.5% 
and 97.5 percentile] per sample and marker. Median sequence coverage per amplicon over all sequenced samples 
agreed well between pre- and post-treatment samples (Supplementary file, Table S1). Two paired samples had to 
be excluded from the PCR-correction analysis because of poor DNA quality and limited DBS starting material for 
two of the post-treatment samples.
Definition of cut-off settings. The most crucial part in generating robust genotyping results from deep 
sequencing of amplicons was the definition of cut-off settings. On the one hand, a stringent cut-off is required for 
excluding sequencing errors; on the other hand, a less stringent cut-off would be desirable for maximized detec-
tion of minority clones. In view of the robustness and high reproducibility required for genotyping in regulatory 
clinical trials, we aimed for a conservative choice of cut-off setting that would rather overestimate than under-
estimate treatment failure rates. For a rational decision on cut-off settings for the data analysis pipeline, we have 
genotyped P. falciparum in vitro culture strains HB3 and 3D7 mixed in different ratios (Fig. 1).
Controlled conditions with known sequences and defined mixing ratios permitted (i) a thorough validation 
of cut-off settings for stringent haplotype calling and (ii) an evaluation of minority clone detectability at differ-
ent cut-off settings. Applying cut-off settings of a minimum of 10 reads/haplotype and 50 reads/sample, all five 
AmpSeq markers identified the original haplotypes HB3 and 3D7 correctly at six different ratios (Fig. 1). The 
minority clone was detected correctly up to the highest dilution of 1:1500. However, applying the chosen default 
cut-off of 1% censored minority clones in all dilutions exceeding a ratio of 1:100. Minority clones are robustly 
detected up to a dilution ratio of 1:100 when applying these default cut-off settings.
Reproducibility of results was assessed by analysing independent triplicates from HB3/3D7 control mixtures 
generated by the same AmpSeq protocol as used for field samples. Comparing haplotypes in all three replicates 
permitted detection of false haplotype calls that might originate from either PCR artefacts or cross- sample or 
environmental DNA contamination and occur in one of the replicates. False ama1-D3 and csp haplotypes were 
found in a single replicate of one control sample (Fig. 1, right panel).
The false csp haplotype calls fell below 1% within-host frequency cut-off. We found that erroneous haplotypes 
occurred only in 1/3 replicates and were rarely observed in the HB3/3D7 control samples. Resulting true hap-
lotypes were called with a minimum occurrence in at least two of the replicates to prevent erroneous haplotype 
calling resulting from rare PCR contamination. These control experiments highlighted, that performing AmpSeq 
genotyping for each sample in triplicate was essential for a reliable exclusion of erroneous haplotypes.
Haplotype diversity of 5 AmpSeq markers in baseline samples. The genetic diversity of 5 molecular 
markers was assessed in 34 baseline samples with regards to number of SNPs observed per amplicon, number 
of haplotypes, mean multiplicity of infection (MOI) and expected heterozygocity, He. In our baseline samples, 
marker cpmp showed highest discriminatory power with 63 haplotypes followed by markers cpp and ama1-D3 
(51 and 43 haplotypes) (Table 1). Less diversity was detected for markers csp and msp7 (29 and 24 haplotypes). In 
agreement with the original WHO/MMV recommended genotyping approach, the three best performing mark-
ers, cpmp, cpp, and ama1-D3, were selected based on their He values as genotyping markers for the present study.
Marker msp7 showed 3 dominant haplotypes accounting for 50% of all msp7 sequence reads (Fig. 2). The like-
lihood that two unrelated parasites share by chance the same haplotype is therefore greater for marker msp7 com-
pared to other markers. This chance effect could lead to underestimation of MOI and misclassification of NI as R 
by marker msp7. Consequently, we excluded marker msp7 from the analysis of the present set of paired samples. 
Yet, marker msp7 may well prove useful for other study sites, where this marker may have a greater discriminatory 
power. Similarly, marker csp showed slightly smaller diversity in baseline samples, where one predominant allele 
was observed with a frequency of 11.5% (Fig. 2). In case of missing data by any of the three prioritized markers, 
the result of backup marker csp was utilized.
Mean multiplicity of infection (MOI) determined by all 5 AmpSeq markers in baseline samples was compared 
to MOI of the established length-polymorphic genotyping marker msp2, which had been reported for the same 
samples previously8 (Fig. 3). AmpSeq-based mean MOI was highest for marker cpmp (MOI = 2.67) and lowest 
for marker msp7 (MOI = 2.15), likely owing to the occurrence of three dominant msp7 haplotypes. We observed 
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Figure 1. Haplotypes detected in experimental mixtures of P. falciparum strains HB3 and 3D7. Proportion 
of ama1-D3, cpmp, cpp, csp, and msp7 haplotype reads from mixtures of two P. falciparum in vitro culture 
strains HB3 (green) and 3D7 (red) (left panel) and detection of rarely observed, contaminating haplotypes 
(right panel). HB3 / 3D7 ratios 1:10 to 1:1500. Y-axis: proportion of reads. Dashed horizontal lines: cut-off for 
minority clones set at 1% of total reads. No data was available for one of the replicates of markers cpp, csp and 
msp7 of ratio 1:10.
Marker
Size 
(bp)
Number of 
SNPs Haplotypes He MOI
cpmp 394 56 63 1.00 2.67
PF3D7_0104100
cpp 362 29 51 1.00 2.67
PF3D7_1475800
ama1-D3 493 16 43 0.98 2.51
PF3D7_1133400
csp 298 16 29 0.97 2.63
PF3D7_0304600
msp7 343 25 24 0.91 2.15
PF3D7_1335100
Table 1. Haplotype diversity of selected AmpSeq markers in 34 pre-treatment samples.
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good concordance in mean MOI among the three prioritized AmpSeq markers as well as with the established and 
widely used length-polymorphic markers msp1 and msp2 (Fig. 3). Diversity of marker glurp is high in sequenc-
ing data repositories, but strong amplification bias during PCR obviously led to a significantly lower glurp MOI 
compared to MOI by marker msp1 and msp2 (p < 0.05 Wilcoxon test). Such a loss of the longer glurp fragments 
through size-mediated amplification bias in multi-clone infections has been described previously8.
AmpSeq genotyping of paired pre- and post-treatment samples. A total of 34 archived paired 
pre- and post-treatment samples from in vivo clinical drug trials were genotyped for PCR-correction using 
AmpSeq. Markers ama1-D3, cpmp, and cpp with the highest discriminatory power were chosen for genotyping. 
In case a marker failed to amplify, csp was used to complement a full set of three individual markers. In three 
post-treatment samples, marker cpmp failed to achieve sufficient sequencing depth and marker csp was used 
instead.
Pre- and post-treatments samples were run in triplicates to prevent any overestimation of haplotypes resulting 
from PCR artefacts or PCR contamination. A haplotype needed to occur in at least two out of three independent 
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Figure 2. Haplotype frequencies for five AmpSeq markers in 34 pre-treatment samples.
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Figure 3. Mean multiplicity of infection (MOI) in 34 pre-treatment samples. MOI determined in 34 pre-
treatment samples by five AmpSeq markers (A) and three length-polymorphic markers (B; data published 
previously8) (*p < 0.05 Wilcoxon test).
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replicates to be considered as a true haplotype. In a first step, the results of individual markers were classified. A 
sample pair was classified as R, if one or more haplotypes occurred in at least two replicates of both, the pre- and 
post-treatment samples, at a within-host haplotype frequency of ≥1%. A NI was defined by the presence of only 
new haplotypes in the post-treatment sample. Figure 4 illustrates an example for each of three possible genotyp-
ing outcomes: (i) a clear R with concordant results by all three markers (left panel), (ii) a clear NI (middle panel), 
and (iii) a discordant outcome where one marker disagreed with results of the other two markers (right panel). 
Haplotype calls of markers ama1-D3, cpmp, and cpp is shown at day 0 (pre-treatment sample) and day X (day of 
recurrent parasitemia). Additional figures for all remaining samples are provided in Supplementary file, Fig. S1 
and S2. The individual genotyping results derived from markers ama1-D3, cpp, cpmp (or csp, in case of missing 
cpmp data in three samples) agreed in 81% (26/32) of sample pairs. AmpSeq identified 15 clear recrudescences 
and 11 clear new infections (Fig. 5, left panel). Discordant results among the three markers were seen in six sam-
ple pairs.
Comparison of PCR-correction results by AmpSeq versus fragment-length polymorphic markers. 
The 32 sample pairs analyzed by AmpSeq had been genotyped previously using length-polymorphic markers 
msp1, msp2, and glurp8. These earlier results were used in this study for a direct comparison of the two genotyp-
ing methods (Fig. 5, right panel). Eight clear NI were observed plus 13 clear R, whereas the remaining 11 pairs 
presented different results in one marker and thus were classified as discordant. For length-polymorphism based 
genotyping, more sample pairs were discordant among the three markers than for AmpSeq genotyping. Msp1, 
msp2, and glurp genotyping results were concordant for 21/32 pairs, whereas by AmpSeq genotyping, 26/32 pairs 
gave concordant results (Fig. 5). Thus, the proportion of discordant results was substantially reduced from 34% 
(11/32) by length-polymorphic markers to 19% (6/32) by AmpSeq markers.
In a second step, the final PCR correction outcome for sample pairs with discordant results among the three 
markers was determined. The six discordant AmpSeq results were resolved using two alternative algorithms, 
the WHO recommended approach1 and the 2/3 algorithm8. Following the WHO approach, all six discordances 
would be classified as NI, because at least one of three markers indicated NI (Fig. 6, left panel). In contrast, by 
the 2/3 algorithm, the matching result of two markers will determine the final outcome. Accordingly, two of six 
discordant samples by AmpSeq were classified as NI, because two markers indicated NI, whereas the remaining 
four discordances showed R in two markers and were thus classified R in the overall result.
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Figure 4. PCR-correction outcomes by AmpSeq for three sample pairs from Day 0/Day X. Within-host 
haplotype frequencies are shown for AmpSeq markers ama1-D3, cpmp, and cpp, quantified in three replicates 
(Rep1 to Rep3) for each of the Day 0 and Day X samples. Different haplotypes of a marker are represented by 
different shapes and colours. Left panel represents a clear recrudescence because of concordant results by all 3 
markers; middle panel: clear new infection; right panel: discordant results whereby result from marker ama1-D3 
(NI) contrasts with that from cpmp (R) and cpp (R).
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Also for length-polymorphic markers, the final PCR correction outcome was determined by both algorithms, 
WHO and 2/3 (Fig. 6, right panel; data published previously8). By WHO algorithm, all 11 discrepant samples 
would be classified as NI but according to the 2/3 algorithm, eight of these would be classified R. Thus, when 
using length-polymorphic markers for genotyping, the algorithm selected had a profound effect on treatment fail-
ure rates, with eight paired samples classified differentially. This effect was much less pronounced with AmpSeq, 
where only three paired samples showed different final outcomes when using the different algorithms. The 
Figure 5. Genotyping results by three molecular markers for 32 paired pre- and post-treatment samples. 
Individual marker results for ama1-D3, cpmp and cpp by AmpSeq (left panel) and length-polymorphic markers 
msp2, msp1 and glurp (right panel) are shown. Blue cell: Recrudescence. Orange cell: New Infection. Grey cell: 
Result of marker csp was used for 3 samples where marker cpmp failed to amplify.
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smaller number of differences observed with AmpSeq implies that more robust results are generated. Using the 
2/3 algorithm, both genotyping techniques resulted in similar numbers of treatment failures, with 59.4% (19/32) 
by AmpSeq and 65.6% (21/32) by length-polymorphic markers. This difference between final outcomes was not 
statistically significant (McNemars test; p = 0.480).
This comparison of two classification algorithms and two genotyping techniques indicated that AmpSeq is 
preferable due to more concordant results, and that the 2/3 algorithm produced most overlap between the two 
genotyping methods.
Discussion
This study explored the utility of amplicon deep sequencing for P. falciparum genotyping in regulatory clinical 
trials to assess antimalarial drug efficacy. We showed that down-selected AmpSeq markers together with strin-
gent bioinformatics data analyses produced high quality data, a critical pre-requisite for use in highly regulated 
PCR-correction of drug failure rates. Genotyping P. falciparum clones by AmpSeq offers a number of advantages 
over other techniques: (i) reproducibility of results is very good as indicated by replicate experiments, sporadic 
contaminants can be identified and eliminated by performing replicates, (ii) the detection limit of minority clones 
is clearly defined and not subject to amplification bias owing to different length of the alleles, (iii) multi-clone 
infections are precisely numbered and unequivocally genotyped, and (iv) the option to quantify each clone and to 
track its frequency over time gives additional information about the dynamics of resistant clones.
For PCR-correction in regulatory trials, high reproducibility of the typing technique is essential. This was 
demonstrated by performing three independent replicates of each blood sample. Triplicates were extremely help-
ful to identify true haplotypes in a very robust manner. This implies additional costs for PCR and sequencing, yet, 
it is an essential approach to minimize or even eliminate artefacts leading to false haplotypes.
For longitudinal tracking of clones during the clinical trial period over several weeks, the sensitivity of 
minority clone detection is crucial. A drug resistant clone might be present only as a small proportion of the 
pre-treatment parasite population in a host, yet, this clone might survive, expand after treatment and even persist 
despite new incoming clones. For the detection of such a recrudescence, it is of key importance that all haplotypes 
or size-polymorphic alleles of the recurrent multi-clonal infection are equally well amplified. Major size difference 
between co-amplified size-polymorphic marker alleles impedes the detectability of clones carrying larger frag-
ment sizes, whereas by AmpSeq such amplification bias has not been observed.
Targeted deep amplicon sequencing in principle is very sensitive to detect minority clones. In our previous 
work the detection limit of a minority clone was as low as 1:1000 given a sufficient read coverage15. In validation 
experiments for all used AmpSeq markers of the present study, minority clones were detected even up to a ratio 
of 1:1500 in mixtures of P. falciparum strains HB3 and 3D7 (Fig. 1). In the context of the current application in 
a clinical trial, however, we chose a cut-off ≥1% within-host-haplotype frequency for accepting a haplotype in 
our study. Despite the high sensitivity for minority clones observed in AmpSeq validation, this was done for two 
reasons: (i) We aimed to prevent as much as possible signals from persisting gametocytes or residual DNA that 
might be misclassified as recrudescent parasites, which would lead to overestimation of treatment failure rates18,19. 
Earlier reports showed that hosts after artemisinin-based combination therapy, who were gametocyte-negative by 
microscopy, still carried sub-microscopic gametocytes detectable by pfs25 QT-NASBA during trial follow up20. In 
Figure 6. Comparison of PCR-correction outcomes determined by AmpSeq and length-polymorphic 
genotyping for 32 paired pre- and post-treatment samples. PCR-correction outcomes were generated by 
AmpSeq markers (left panel) versus length-polymorphic markers sized by capillary electrophoresis (right panel; 
published data8). For 3/32 sample pairs marker cpmp failed to amplify and was replaced by marker csp). For 
resolving discordant results between the three markers, both the WHO and the “two out of three markers” (2/3) 
algorithms were applied.
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the present clinical trial, it remains unclear, whether gametocytes survived ACT-treatment or derived from recur-
rent parasitemia. (ii) A further aim was to minimize false haplotypes arising from contamination, as occasionally 
observed in control samples of mixed P. falciparum DNA from in vitro culture (Fig. 1, right panel).
Several parameter estimates were compared between AmpSeq and length-polymorphic markers. Multiplicity 
of infection, i.e. the mean number of concurrent clones per sample, was highly concordant between the estab-
lished length-polymorphic markers msp1 and msp2 and AmpSeq markers (Fig. 3). Also, the genetic diversity was 
comparable between AmpSeq and length-polymorphic markers in the samples analysed.
The robust detection of minority clones at frequencies as low as 1:100 by AmpSeq represents a key advan-
tage over the established msp1, msp2 and glurp protocol3 that has been used routinely for many years. In 
length-polymorphism-based genotyping, the sensitivity for minority clones greatly depended on the differ-
ence in amplicon sizes of mixed strains and a minority clone was only detectable up to a ratio of 1:5 for mixed 
strains 3D7 / K1 of marker msp18. PCR template competition (also known as allelic suppression) acts on 
PCR fragments that substantially differ in size and are amplified within the same reaction tube. Such biased 
amplification likely operates as a matter of principle, irrespective of the method applied for distinguishing 
alleles of the length-polymorphic marker, i.e. sizing by agarose gel electrophoresis, PCR-restriction fragment 
length-polymorphism and capillary electrophoresis, or by high resolution melt analysis21–23, though all these 
methods differ in their ability to detect minority clones.
Another genotyping technique is based on detection of individual SNPs of a genome-wide distribution and 
generates so-called molecular barcodes24. The major advantage of AmpSeq over molecular barcodes is the poten-
tial of AmpSeq to differentiate individual clones within multi-clone infections, even at high multiplicity. On the 
other hand, major biological limitations in genotyping malaria parasites are not resolvable by neither methods, 
i.e. daily fluctuations in density and parasite sequestration, hindering longitudinal follow up of parasite clones. 
These shortfalls of genotyping derive from biological features of the parasite and remain the same irrespective of 
the typing method used25.
The concordance of results among the three genotyped AmpSeq markers was substantially higher than that 
for length-polymorphic markers. AmpSeq results from markers ama1-D3, cpmp and cpp generally agreed very 
well and classified 15 paired samples as clear recrudescence and additional 11 pairs as clear NI. Only six paired 
samples (6/32, 19%) showed discordant results between the three AmpSeq markers. A possible reason for a dis-
crepancy among the three marker results could be that a NI carries by chance the same haplotype as a parasite 
clone that was present in the pre-treatment sample, but had been successfully cleared. This scenario arising by 
chance would result in a false classification of a true NI as recrudescence. For length-polymorphic markers, the 
same problem of false classification applies and largely depends on marker diversity. In addition, an important 
cause of discrepancies, but only in length-polymorphic markers, is allelic suppression during PCR, which may 
lead to an allele undetected because of its large size and/or low within-host frequency8. This latter problem does 
not occur with AmpSeq markers. Genotyping by AmpSeq therefore is expected to produce more concordant 
results than length-polymorphic markers. Indeed, greater concordance between markers was found for AmpSeq, 
which substantially reduced the number of discrepant results from 34% by length-polymorphic markers to 19% 
by AmpSeq. This greater concordance by AmpSeq markers represents a major advance over length-polymorphic 
markers, primarily because the resolution of discording results among the three markers is conditional upon the 
choice of the WHO versus 2/3 algorithm.
In the past different algorithms were proposed to classify the final PCR-correction outcome in case of dis-
cordant results from three markers1,5,8,9,26. The 2/3 algorithm was proposed following increased awareness of 
amplification competition between length- polymorphic fragments, which could lead to loss of minority clones. 
Recently, Jones and coworkers27 have employed pharmacological models to simulate a drug efficacy trial, includ-
ing therapeutic outcomes and genotyping results based on size-polymorphic markers. In this simulated trial, 
several molecular correction approaches were tested. The 2/3 algorithm for PCR-correction fitted best with the 
simulated treatment failure rates.
For AmpSeq markers we compared both these algorithms. By WHO algorithm, all six discordant results were 
classified as NI, by 2/3 algorithm, four of these were classified as recrudescences based on results of two markers. 
This shows that the WHO recommended approach tends slightly towards NI, in contrast to the 2/3 algorithm. 
In the context of clinical trials of antimalarials, it is preferable to be rather more conservative in identifying 
treatment failure. Following the rationale that overestimation of NI should be avoided as this would prevent the 
detection of a failing drug, the more stringent classification algorithm, i.e. 2/3, seems justified.
On the other hand, it could be argued that the result of a NI by a single AmpSeq marker constitutes a firm 
evidence for presence of only new clones in the post-treatment sample because by AmpSeq no suppression of a 
haplotype owing to size is expected. However, we selected a robust cut-off suitable for a clinical trial, whereby 
a haplotype needed to reach ≥ 1% of the within-host read frequency. This may increase the probability that a 
clone can fall below the cut-off in one of the markers, thus leading to a discordant result between three AmpSeq 
markers. Setting of a read frequency cut-off is required for sequencing data, owing to amplification and sequenc-
ing errors. This necessary restriction is traded off against sensitivity to detect minority clones. Owing to this 
limitation of AmpSeq, we suggest to adopt the 2/3 algorithm also for resolving discordant results from the three 
AmpSeq markers.
From five available AmpSeq markers, we chose three unlinked single-copy genes, ama1-D3, cpmp and cpp, 
because these amplicons showed the highest diversity in the pre-treatment samples. The presentation of allelic 
frequencies in the baseline samples had been recommended in the WHO expert consultation on PCR-correction 
in clinical drug trials1. AmpSeq marker cpp was newly developed for this study and revealed 51 haplotypes. 
This diversity compares to the most polymorphic marker in this study, cpmp, with 63 haplotypes. In a previous 
study conducted in a village in PNG with medium transmission intensity, marker cpmp also had shown highest 
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diversity with 27 haplotypes in 37 blood samples14,15. The clinical samples of the present study mainly derived 
from Africa, suggesting that cpmp is a suitable marker for various geographic areas.
Marker csp in the present study revealed 29 haplotypes in 34 baseline samples, while in the PNG study csp had 
not been sufficiently diverse owing to only three haplotypes identified15. Restricted csp diversity was also reported 
from other geographic regions, e.g in SE-Asia28 and Peru29, whereas csp polymorphism was more pronounced in 
Africa30. These findings of geographically varying csp diversity highlight the importance of assessing the diversity 
of molecular markers for each study site, before embarking on a genotyping study.
Another newly developed AmpSeq marker derived from a highly polymorphic region of msp7. The selected 
msp7 amplicon showed a high value of expected heterozygosity (He = 0.91) in field isolates deposited in the 
MalariaGEN and was therefore developed as a new AmpSeq marker. Within 34 pre-treatment samples analyzed 
in this study, however, msp7 showed the lowest number of haplotypes, with three dominant haplotypes together 
representing 50% allelic frequency. The latter characteristic poses a problem for recrudescence typing, because, 
despite a fully acting drug, any new infection would likely carry one of the frequent genotypes. In high transmis-
sion areas with high MOI, marker msp7 could therefore be prone to misclassification and bias towards recrudes-
cence. Because of these high frequencies of the three dominant msp7 haplotypes we excluded AmpSeq marker 
msp7 from our genotyping panel. However, in other geographic regions, marker msp7 might not be equally 
restricted and could still be useful.
HaplotypR, our bioinformatic data analysis pipeline, was further developed to support fusion of overlapping 
paired sequence reads and to allow haplotype calling in triplicates14,15. For different study types, the haplotype 
calling cut-off settings of HaplotypR can be adjusted to permit more or less stringency. For the application of 
AmpSeq in a clinical trial, a very stringent cut-off of ≥1% within-host haplotype frequency was justified. For 
other applications of AmpSeq the cut-off may be relaxed, for example, if increased sensitivity for detecting minor-
ity clones is required, such as studies of duration of a clonal infection14. Recently HaplotypR was validated in com-
parison to similar bioinformatic pipelines and performed equally well31. AmpSeq data analysis critically depends 
on bioinformatics expertise, an additional requirement for many genotyping laboratories and additional costs. 
On the other hand, the parallel analysis of multiple AmpSeq markers and the technique’s particular suitability 
for multiplexing large samples sizes help to lower costs of genotyping. The ease of shipping amplicons globally 
and ready access to sequencing facilities at academic or commercial resource centres make AmpSeq an option in 
reach also for laboratories in malaria endemic countries.
conclusion. This study showed that AmpSeq genotyping was highly reproducible with robust results that 
compared well to those from the current standard genotyping technique based on length-polymorphic mark-
ers. Performing all AmpSeq experiments in triplicates was an essential precondition for high quality data. We 
concluded that AmpSeq represents an advance over other techniques owing an unbiased amplification and thus 
improved sensitivity and reproducibility in the detection of minority clones. In regulatory clinical trials of anti-
malarial drugs, PCR-correction of failure rates critically depends on the quality of genotyping, we therefore rec-
ommend using AmpSeq, as this technique overcomes major shortfalls of other methods.
Methods
AmpSeq markers. SNP-rich amplicons were selected from 5 marker genes. Three AmpSeq markers, 
the genes for circumsporozoite surface protein (csp, PF3D7_0304600), apical membrane antigen (ama1-D3, 
PF3D7_1133400), and marker PF3D7_0104100, a conserved plasmodium membrane protein (cpmp), had been 
evaluated previously in P. falciparum in vitro culture strains and community samples from Papua New Guinea 
(PNG)14,15. Two additional markers, merozoite surface protein 7 (msp7, PF3D7_1335100) and PF3D7_1475800, 
a conserved plasmodium protein (cpp), were identified using 3411 P. falciparum genomes from 23 countries pub-
lished in the MalariaGEN dataset16 according to selection criteria described previously15. New markers were 
selected based on high values for expected heterozygosity (He) in 200 bp windows spanning the SNP-rich regions 
of the candidate genes. Amplicon sizes were restricted to <450 bp to match length limits of the Illumina MiSeq 
platform. Diversity of all AmpSeq markers used in this study is presented in Supplementary file, Table S2. Primers 
were designed manually in conserved regions flanking the polymorphic fragments, yielding a 331 bp fragment 
for msp7, spanning nucleotide positions 575–905, and a 362 bp fragment for cpp, spanning nucleotide positions 
40–391 (Supplementary file, Table S3). Primers were evaluated in silico to exclude formation of primer dimer or 
secondary structure.
Archived blood samples from clinical trials of antimalarial drugs (artemisinin-based combina-
tion therapy, ACT). A set of 34 pre- and post-treatment sample pairs, which had been used previously for 
evaluation of recrudescence typing with length-polymorphic markers msp2, msp1 and glurp8 was available for 
AmpSeq analysis to permit direct comparison of methods. The post-treatment sample was collected on the day 
of recurrent parasitemia following antimalarial treatment with ACT. The median time of recurrence was 21 days 
(IQR: 14–27 days) post-treatment. These 34 anonymized sample pairs derived from different trial sites across 
Africa and Asia. Therefore, a description of “overall” endemicity is not possible for this set of samples.
ethics statement. Ethical clearance for genotyping of anonymous field samples for the purpose of molecular 
assay validation was obtained from Ethikkommission Nordwest- und Zentralschweiz (EKNZ Req-2016–00050). 
All experiments were performed in accordance with relevant guidelines and regulations. Informed consent was 
obtained from all subjects or, if subjects were under 18, from a parent and/or legal guardian.
In vitro culture stains. Mixtures of P. falciparum strains HB3 and 3D7 at six defined ratios were used to 
determine the limit of detection for minority clones and to validate haplotype calling. Preparation of P. falciparum 
control mixtures was described previously8.
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DnA extraction. For all clinical trials samples, total DNA was extracted from dried blood spots (DBS) on 
Whatman 3MM filter paper. Three disks of 3 mm diameter were punched from a dried blood spot, washed in 
500 µL dH2O and boiled in 35 µL dH2O for 30 min at 98 °C with brief vortexing every 30 sec to elute gDNA. 
Extracted DNA was stored at 4 °C.
primary and nested pcR. To enrich target sequences from extracted total DNA, a primary PCR was 
performed as described previously with the following modifications15. Primary PCRs were prepared in duplex 
(ama1-D3/cpmp) and triplex (csp/cpp/msp7) reactions in a final volume of 15 µL including 3 µL DNA as template, 
250 nm of each primer pair and 7.5 µL KAPA HiFi HotStart Ready Mix (Roche). Primer sequences and thermo 
profiles are provided in the Supplementary file, Tables S3–S6.
Individual nested PCRs (nPCR) were performed for all 5 markers to ensure high yields of product 
(Supplementary file, Table S6). This step added a 5‘-linker for later adapter addition to the primary PCR (pPCR) 
product. nPCR reactions were prepared in a final volume of 15 µL including 1 µL of pPCR product, 250 nm nPCR 
primer pairs and 7.5 µL KAPA HiFi HotStart Ready Mix (Roche). To confirm successful amplification nPCR 
products were run on a 2% agarose gel.
normalisation of npcR products. nPCR products were normalised using a SequalPrepTM Normalisation 
plate (Thermo Fisher Scientific) according to the manufacturer’s instructions. Briefly, 8 µL nPCR products and 
10 µL binding buffer were applied to the normalisation plate. After 1 h incubation, nPCR products were eluted 
in 15 µL elution buffer yielding a final DNA concentration of 1–2 ng/ µL. 5 µL of normalised nPCR products 
(ama1-D3/cpmp or csp/cpp/msp7) were pooled and used as template for adapter PCR.
Multiplexed adapter-addition PCR. Individual samples were barcoded with a unique forward and reverse 
sequence index by performing a third round of PCR, which was performed as duplex (ama1-D3/cpmp) and tri-
plex (csp/cpp/msp7) reaction in a final volume of 15 µL including 1 µL of template DNA, 833 nm adapter primer 
pairs and 7.5 µL KAPA HiFi HotStart Ready Mix (Roche). PCR products were run on a 2% agarose gel.
Amplicon library preparation. Twenty samples of either the ama1-D3/cpmp or the csp/cpp/msp7 mul-
tiplexed adapter-addition PCR reaction were combined to pools of equal molarity. These pools were purified 
with 0.6 volumes of NucleoMag beads (Macherey-Nagel) and quantified by Qubit fluorometer (Thermo Fisher 
Scientific). In a final step, each pool was diluted to 10 nM and combined to a final sequencing library.
illumina MiSeq sequencing. Prior to deep sequencing, correct amplicon sizes in library pools were con-
firmed by Agilent 4200 TapeStation System. Final amplicon libraries were sequenced in two runs on an Illumina 
MiSeq platform in paired-end mode using the MiSeq reagent kit v3 (600 cycles; 2 × 300 bp) including 10% 
spike-in of Enterobacteria phage phiX control v3 (Illumina).
Sequence read analysis and haplotype calling. Deep sequencing reads were analysed using bioinfor-
matic pipeline HaplotypR version 0.3 (https://github.com/lerch-a/HaplotypR/releases/tag/v0.3)14,15. Sequencing 
reads were demultiplexed by sample and by amplicon. Overlapping sequence of paired reads were merged using 
software vsearch (parameters:–fastq_mergepairs–fastq_truncqual 1–fastq_maxns 0)32 and clustered using soft-
ware swarm33. Samples that showed a read coverage <50 reads per sample were excluded from the analysis. 
SNP calling required a minimum 50% mismatch rate and a minimum occurrence in 2 independent samples15. 
The term haplotype in our work denotes “unique sequence variant of an entire amplicon”. Haplotypes result-
ing from insertion and deletion (indels), chimeric or singleton reads were removed and thus excluded from 
further analysis. Haplotype calling followed stringent cut-off criteria and required: (i) a minimum read cover-
age of 10 reads per haplotype and sample, (ii) a within-host haplotype frequency ≥1%, and (iii) a minimum 
occurrence of the haplotype in 2 out of the 3 replicates. Haplotypes occurring only once among triplicates of a 
sample were excluded. Within-host-haplotype frequency was derived from the number of reads per haplotype 
per amplicon over the sum of all reads per amplicon in a sample. Final haplotype sequences obtained in this 
study were deposited in GenBank under the accession numbers MK975258 - MK975308 (csp), MK975309 - 
MK975380 (ama1-D3), MK981569-MK981614 (msp7), MN010910 - MN010993 (PF3D7_0104100), MN010994 
- MN011066 (PF3D7_1475800).
Classification of samples into new infection and recrudescence. The final PCR-correction were 
established in two steps. In the first step, the genotyping result, i.e. new infection (NI) or recrudescence (R) 
was determined for each of the three markers ama1-D3, cpmp and cpp according to the following criteria: 
Classification of recrudescence (R) required that at least one of the haplotypes occurred in both, the pre- and 
post-treatment sample, with a minimum haplotype frequency of 1% in at least two of the three independ-
ent replicates performed. A new infection (NI) was defined by the occurrence of only new haplotypes in the 
post-treatment sample with a minimum haplotype frequency of 1%. This definition corresponds to that one 
established in 2007 by experts in the field during a WHO/MMV-convened meeting on genotyping methods for 
clinical trials on antimalarial drug efficacy1.
In the second step, the final outcome for each sample was derived from all three markers, ama1-D3, cpmp 
and cpp. In case any of the markers fell below the minimum read criterion, marker csp was used to comple-
ment a full set of three markers. In case all markers agreed, this concordant result was directly reported as final 
PCR-corrected treatment outcome. In case R and NI classification of individual markers disagreed, two different 
approaches (here called algorithms) were applied to resolve the discordancy: (i) The WHO/MMV recommended 
approach1, where a recurrent parasitemia is classified in the overall outcome as NI, if at least one of the three 
markers had given a NI result. (ii) The alternative, newer approach termed “2/3 algorithm”8. This algorithm uses 
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the consensus of two markers as final PCR-correction outcome. We report the PCR-correction results for both 
algorithms, and discuss their respective benefits.
Data availability
The datasets generated and analysed in the course of this study are available in NCBI Sequence Read Archive 
repository under accession numbers SRR8608898 and SRR8608897. Haplotype sequences were deposited in 
GenBank under the accession numbers MK975258 - MK975308 (csp), MK975309 - MK975380 (ama1-D3), 
MK981569-MK981614 (msp7), MN010910 - MN010993 (PF3D7_0104100), MN010994 - MN011066 
(PF3D7_1475800). The source code for software HaplotypR version 0.3.1 is available at https://github.com/
lerch-a/HaplotypR/releases/tag/v0.3.1.
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